SHPH (Shuttle Pharmaceuticals Holdings) Cash And Cash Equivalents : $4.51 Mil (As of Mar. 2025)

View and export this data going back to 2022. Start your Free Trial

What is Shuttle Pharmaceuticals Holdings Cash And Cash Equivalents?

Shuttle Pharmaceuticals Holdings's quarterly cash and cash equivalents increased from Sep. 2024 ($0.16 Mil) to Dec. 2024 ($1.92 Mil) and increased from Dec. 2024 ($1.92 Mil) to Mar. 2025 ($4.51 Mil).

Shuttle Pharmaceuticals Holdings's annual cash and cash equivalents declined from Dec. 2022 ($8.42 Mil) to Dec. 2023 ($2.58 Mil) and declined from Dec. 2023 ($2.58 Mil) to Dec. 2024 ($1.92 Mil).

Shuttle Pharmaceuticals Holdings Cash And Cash Equivalents Historical Data

The historical data trend for Shuttle Pharmaceuticals Holdings's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shuttle Pharmaceuticals Holdings Cash And Cash Equivalents Chart

Shuttle Pharmaceuticals Holdings Annual Data

Trend

Dec20

Dec21

Dec22

Dec23

Dec24

Cash And Cash Equivalents

0.12

0.51

8.42

2.58

1.92

Shuttle Pharmaceuticals Holdings Quarterly Data
	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25
Cash And Cash Equivalents	Get a 7-Day Free Trial													1.40	0.70	0.16	1.92	4.51

Shuttle Pharmaceuticals Holdings Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Shuttle Pharmaceuticals Holdings (NAS:SHPH) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Shuttle Pharmaceuticals Holdings Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Shuttle Pharmaceuticals Holdings's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Shuttle Pharmaceuticals Holdings Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Shuttle Pharmaceuticals Holdings Inc (NAS:SHPH) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

401 Professional Drive, Suite 260, Gaithersburg, MD, USA, 20879

Website

https://www.shuttlepharma.com

Shuttle Pharmaceuticals Holdings Inc is a clinical-stage pharmaceutical company leveraging its proprietary technology to develop novel therapies designed to cure cancers. The company's goal is to extend the benefits of cancer treatments with surgery, radiation therapy, chemotherapy and immunotherapy. Radiation therapy (RT) is one of the effective modalities for treating cancers. It is developing a pipeline of products designed to address the limitations of the current cancer therapies as well as to extend to the new applications of RT. The company believes that its product candidates will enable the company to deliver cancer treatments that are safer, more reliable and at a greater scale than that of the current standard of care.

Executives

Milton Brown	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Bette Jacobs	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., 1 RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Peter Dritschilo	officer: President and COO	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Anatoly Dritschilo	director, 10 percent owner, officer: CEO and Chairman	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Tyvin Rich	officer: Chief Medical Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Mira Jung	officer: Chief Scientific Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Hoek Michael Vander	officer: Chief Financial Officer	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., SUITE 450, ROCKVILLE MD 20850
Chris Senanayake	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Steven M Richards	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
William Adkins	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850
Joshua Schafer	director	SHUTTLE PHARMACEUTICALS HOLDINGS, INC., ONE RESEARCH COURT, SUITE 450, ROCKVILLE MD 20850